Atrial fibrillation: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (12 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{| class="infobox" style="float:right;" | {| class="infobox" style="float:right;" | ||
|- | |- | ||
| [[File:Siren.gif|30px|link=Atrial fibrillation resident survival guide]]|| <br> || <br> | |[[File:Siren.gif|30px|link=Atrial fibrillation resident survival guide]]||<br>||<br> | ||
| [[Atrial fibrillation resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']] | |[[Atrial fibrillation resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']] | ||
|} | |} | ||
{| class="infobox" style="float:right;" | {| class="infobox" style="float:right;" | ||
|- | |- | ||
| [[Image:Heart conduct sinus.gif|150px|]]<BR><small>'''Sinus rhythm'''</small> | |[[Image:Heart conduct sinus.gif|150px|]]<BR><small>'''Sinus rhythm'''</small> | ||
|} | |} | ||
{| class="infobox" style="float:right;" | {| class="infobox" style="float:right;" | ||
|- | |- | ||
| [[Image:Heart conduct atrialfib.gif|150px]]<BR><small>'''Atrial fibrillation'''</small> | |[[Image:Heart conduct atrialfib.gif|150px]]<BR><small>'''Atrial fibrillation'''</small> | ||
|} | |} | ||
{{Atrial fibrillation}} | |||
{{Patient}} | {{Patient}} | ||
{{CMG}} | {{CMG}} {{AE}} {{Anahita}} {{Laith}} | ||
{{SK}} AF; afib; lone fibrillator | {{SK}} AF; afib; lone fibrillator | ||
==[[Atrial fibrillation overview|Overview]]== | ==[[Atrial fibrillation overview|Overview]]== | ||
==[[Atrial fibrillation historical perspective|Historical Perspective]]== | |||
==[[Atrial fibrillation classification|Classification]]== | ==[[Atrial fibrillation classification|Classification]]== | ||
| Line 45: | Line 46: | ||
==[[Atrial fibrillation overview of treatment|Treatment]]== | ==[[Atrial fibrillation overview of treatment|Treatment]]== | ||
===[[Atrial fibrillation rate control|Rate and Rhythm Control]]=== | |||
[[Atrial fibrillation rate control|Rate Control]] | [[Atrial fibrillation maintenance of rate control and sinus rhythm|Maintenance of Sinus Rhythm]] | |||
===Cardioversion=== | ===Cardioversion=== | ||
[[Atrial fibrillation cardioversion|Overview]] | [[Atrial fibrillation electrical cardioversion|Electrical Cardioversion]] | [[Atrial fibrillation pharmacological cardioversion|Pharmacological Cardioversion]] | [[Atrial fibrillation cardioversion|Overview]] | [[Atrial fibrillation electrical cardioversion|Electrical Cardioversion]] | [[Atrial fibrillation pharmacological cardioversion|Pharmacological Cardioversion]] | ||
| Line 53: | Line 57: | ||
===Dabigatran=== | ===Dabigatran=== | ||
[[dabigatran#Dosing|Dosing]] | [[Dabigatran#Surgery and Interventions|Discontinuation for Surgery and Interventions]] | [[Dabigatran#WARNINGS AND PRECAUTIONS| Warnings and Precautions]] | [[Dabigatran#Adverse Reactions|Adverse Reactions]] | [[Dabigatran#Use in Specific Populations|Use in Specific Populations Such as Pregnancy]] | [[Dabigatran#Overdosage|Overdosage]] | [[Clinical Pharmacology of Dabigatran|Clinical Pharmacology]] | [[FDA Review of Data From the RE-LY Trial on September 20th, 2010|FDA Review of the RE-LY Data]] | [[A comparison of the RE-LY and Rocket AF Trials ]] | [[Estimates of Cost Per Year of Life Saved for Dabigatran]] | [[dabigatran#Dosing|Dosing]] | [[Dabigatran#Surgery and Interventions|Discontinuation for Surgery and Interventions]] | [[Dabigatran#WARNINGS AND PRECAUTIONS| Warnings and Precautions]] | [[Dabigatran#Adverse Reactions|Adverse Reactions]] | [[Dabigatran#Use in Specific Populations|Use in Specific Populations Such as Pregnancy]] | [[Dabigatran#Overdosage|Overdosage]] | [[Clinical Pharmacology of Dabigatran|Clinical Pharmacology]] | [[FDA Review of Data From the RE-LY Trial on September 20th, 2010|FDA Review of the RE-LY Data]] | [[A comparison of the RE-LY and Rocket AF Trials ]] | [[Estimates of Cost Per Year of Life Saved for Dabigatran]] | ||
===Ablation=== | ===Ablation=== | ||
| Line 62: | Line 63: | ||
===Surgery=== | ===Surgery=== | ||
[[Atrial fibrillation surgical treatment|Maze Open Heart Surgery]] | [[Atrial fibrillation surgical treatment|Maze Open Heart Surgery]] | ||
===[[Atrial fibrillation secondary prevention|Secondary Prevention]]=== | ===[[Atrial fibrillation secondary prevention|Secondary Prevention]]=== | ||
| Line 79: | Line 73: | ||
==Related Chapters== | ==Related Chapters== | ||
* [[Atrial flutter]] | |||
* [[Ashman phenomenon]] | *[[Atrial flutter]] | ||
* [[The Living Guidelines: Diagnosis and Management of Atrial Fibrillation | The AF Living Guidelines: Vote on current recommendations and suggest revisions to the guidelines]] | *[[Ashman phenomenon]] | ||
*[[The Living Guidelines: Diagnosis and Management of Atrial Fibrillation | The AF Living Guidelines: Vote on current recommendations and suggest revisions to the guidelines]] | |||
{{Electrocardiography}} | {{Electrocardiography}} | ||
| Line 94: | Line 89: | ||
[[Category:Electrophysiology]] | [[Category:Electrophysiology]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
[[Category:Up-To-Date Cardiology]] | [[Category:Up-To-Date Cardiology]] | ||
Revision as of 03:26, 14 December 2022
 |
Resident Survival Guide |
 Sinus rhythm |
 Atrial fibrillation |
|
Atrial Fibrillation Microchapters | |
|
Special Groups | |
|---|---|
|
Diagnosis | |
|
Treatment | |
|
Cardioversion | |
|
Anticoagulation | |
|
Surgery | |
|
Case Studies | |
|
Atrial fibrillation On the Web | |
For patient information, click here. Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Anahita Deylamsalehi, M.D.[2] Laith Adnan Allaham, M.D.[3]
Synonyms and keywords: AF; afib; lone fibrillator
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Atrial Fibrillation from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Special Groups
Postoperative AF | Acute Myocardial Infarction | Wolff-Parkinson-White Preexcitation Syndromes | Hypertrophic Cardiomyopathy | Hyperthyroidism | Pulmonary Diseases | Pregnancy | Patients Presenting with ACS and/or PCI or Valve Intervention
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | EKG Examples | Afib with LBBB EKG Examples | Chest X Ray | Echocardiography | Holter Monitoring and Exercise Stress Testing | Cardiac MRI
Treatment
Rate and Rhythm Control
Rate Control | Maintenance of Sinus Rhythm
Cardioversion
Overview | Electrical Cardioversion | Pharmacological Cardioversion
Anticoagulation
Overview | Warfarin | Converting from or to Warfarin | Converting from or to Parenteral Anticoagulants | Dabigatran
Dabigatran
Dosing | Discontinuation for Surgery and Interventions | Warnings and Precautions | Adverse Reactions | Use in Specific Populations Such as Pregnancy | Overdosage | Clinical Pharmacology | FDA Review of the RE-LY Data | A comparison of the RE-LY and Rocket AF Trials | Estimates of Cost Per Year of Life Saved for Dabigatran
Ablation
Catheter Ablation | AV Nodal Ablation | Surgical Ablation